The emerging agenda of stratified medicine in neurology (Q38169977)

30 August 2017

The emerging agenda of stratified medicine in neurology (English)

1 reference

30 August 2017

Paul M Matthews

1

0 references

author name string

Paul Edison

series ordinal

2

1 reference

30 August 2017

Olivia C Geraghty

series ordinal

3

1 reference

30 August 2017

Michael R Johnson

series ordinal

4

1 reference

30 August 2017

language of work or name

English

0 references

publication date

10 December 2013

1 reference

30 August 2017

Nature Reviews Neurology

1 reference

30 August 2017

10

1 reference

30 August 2017

1

1 reference

30 August 2017

15-26

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2013.245

30 August 2017

0 references

cites work

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Medicine. (De)personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Personalized medicine in oncology: the future is now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Prevention of ischemic stroke: overview of traditional risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Beneficial Effect of Carotid Endarterectomy in Symptomatic Patients with High-Grade Carotid Stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Validation of Clinical Classification Schemes for Predicting Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Using pharmacogenetics in real time to guide warfarin initiation: a clinician update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Genetic basis for idiosyncratic reactions to antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Newly diagnosed epilepsy and pharmacogenomics research: a step in the right direction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Pharmacogenomics in neurology: current state and future steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Early identification of refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

A twin study of genetic influences on epilepsy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Molecular genetics of Dravet syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

De novo mutations in epileptic encephalopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Personalized medicine in multiple sclerosis: hope or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Translation towards personalized medicine in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Defining and scoring response to IFN-β in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Predicting responders to therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Environmental factors and their regulation of immunity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

MRI criteria for MS in patients with clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

A reassessment of the plateauing relationship between T2 lesion load and disability in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

MRI as a marker for disease heterogeneity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Increased PK11195 PET binding in the cortex of patients with MS correlates with disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Association between clinical disease activity and Epstein-Barr virus reactivation in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Plasma osteopontin levels in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Transcription-based prediction of response to IFNbeta using supervised computational methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Diagnosis and treatment of dementia: 2. Diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

The use of PET in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Genome-wide association studies, Alzheimer disease, and understudied populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Twenty years of Alzheimer's disease-causing mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Biomarkers for Alzheimer's disease therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Imaging biomarkers in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Comparing predictors of conversion and decline in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

The Path to Personalized Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Predictive, personalized, preventive, participatory (P4) cancer medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

The Alberta Stroke Program Early CT Score in clinical practice: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Next generation sequencing for molecular diagnosis of neuromuscular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Impacts of massively parallel sequencing for genetic diagnosis of neuromuscular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

RNA-Seq: a revolutionary tool for transcriptomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Comorbidity delays diagnosis and increases disability at diagnosis in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Web-based patient-reported outcomes in drug safety and risk management: challenges and opportunities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

The cellular pathology of lysosomal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

The microeconomics of personalized medicine: today's challenge and tomorrow's promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Association of smoking with risk of multiple sclerosis: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Vitamin D in MS: A vitamin for 4 seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Plaque Ulceration and Lumen Thrombus Are the Main Sources of Cerebral Microemboli in High-grade Internal Carotid Artery Stenosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Human apolipoprotein E: the Alzheimer's disease connection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Targeted next-generation sequencing as a comprehensive test for patients with and female carriers of DMD/BMD: a multi-population diagnostic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

Exon-skipping therapy for Duchenne muscular dystrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2013.245

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

31 March 2020

1 reference

12 December 2020

Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study

1 reference

12 December 2020

The therapeutic potential of antisense-mediated exon skipping

1 reference

12 December 2020

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation

1 reference

12 December 2020

10.1038/NRNEUROL.2013.245

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference